Pulmonx Corporation (LUNG)
LUNGNASDAQ-GSMedical/Dental Instruments
$3.03
+0.2300 (+8.21%) today
At the close, Nov 10, 4:00 PM ET. Pre-market $3.05 +8.93%
- Market cap
- $132.83m
- P/E
- –
- EPS, last 4 quarters
- $-1.01
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.13 to $3.25
- Average volume
- 653.4k
- Previous close
- $2.80
Analysts
3 coveringBuy2 buy, 1 hold, 0 sell
Targets a year out average $3.63, +19.8% from here
Earnings
next estimate $-0.2300Next report
Dec 2025
+35.9%
Mar 2026
0.0%
Jun 2026
+14.3%
Sep 2026
+26.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $22.60m | $20.59m | $22.76m | $22.84m |
| Gross profit | $17.54m | $16.04m | $17.74m | $17.40m |
| Operating income | -$9.90m | -$12.96m | -$9.06m | -$7.49m |
| Net income | -$10.43m | -$13.65m | -$10.08m | -$8.39m |
Last four quarters: revenue $88.78m, margin -47.9%, free cash flow -$25.61m
News
8 latest- Pulmonx: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 3 days ago
- All You Need to Know About Pulmonx (LUNG) Rating Upgrade to BuyZacks · Oct 30, 2026
- Pulmonx Reports 6% Q3 Revenue Growth, Narrows Loss And Maintains 2026 Revenue Outlook RTTNews · Oct 29, 2026
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30% RTTNews · Oct 28, 2026
- Pulmonx (LUNG) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 27, 2026
- What Pulmonx (LUNG) Said on Its Q3 Earnings CallMarketBeat · Oct 27, 2026
- Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 27, 2026
- Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?Zacks · Aug 26, 2026
The company
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr Endobronchial Valve following its designation as a 'breakthrough device.' The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- pulmonx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.